Detailed Information
Cited 4 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+locally advanced or metastatic urothelial carcinoma (UC) in Asian patients
- Authors
- Ye, D[Ye, D.]; Liu, J[Liu, J.]; Zhou, A[Zhou, A.]; Zou, Q[Zou, Q.]; Li, H[Li, H.]; Fu, C[Fu, C.]; Hu, H[Hu, H.]; Huang, J[Huang, J.]; Zhu, S[Zhu, S.]; Jin, J[Jin, J.]; Ma, L[Ma, L.]; Guo, J[Guo, J.]; Xiao, J[Xiao, J.]; Park, SH[Park, S. H.]; Zhang, D[Zhang, D.]; Qiu, X[Qiu, X.]; Bao, Y[Bao, Y.]; Zhang, L[Zhang, L.]; Shen, W[Shen, W.]; Feng, B[Feng, B.]
- Issue Date
- Oct-2019
- Publisher
- OXFORD UNIV PRESS
- Citation
- ANNALS OF ONCOLOGY, v.30, pp.367 - 367
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 30
- Start Page
- 367
- End Page
- 367
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.